Working… Menu

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02380274
Recruitment Status : Active, not recruiting
First Posted : March 5, 2015
Last Update Posted : October 21, 2019
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:

The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Condition or disease
Prostate Cancer Castration-resistant Prostate Cancer Metastatic Prostate Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 1030 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States
Actual Study Start Date : March 27, 2015
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Patients with CRPC
Patients with CRPC

Primary Outcome Measures :
  1. Number of CRPC Treatment Patterns [ Time Frame: Up to 6 years following enrollment onto the study ]
    Treatment patterns will be described according to: The distribution and timing of disease assessment methods (PSA, other laboratory testing, imaging); Treatment settings; Physician referral patterns from urologist to oncologist (occurrence and timing of referrals) where applicable; CRPC treatments, including initial choices, sequencing and entry into interventional clinical trials

  2. Health-related Quality of Life (HRQoL) as assessed by Modified Total Illness Burden Index (TIBI-CaP) [ Time Frame: Baseline ]
  3. HRQoL as assessed by SF-12v2 Health Survey [ Time Frame: Baseline and up to 6 years approximately every 3 months ]
  4. HRQoL as assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) [ Time Frame: Baseline and up to 6 years approximately every 3-6 months ]
  5. HRQoL as assessed by Brief Pain Inventory - Short Form (BPI-SF) [ Time Frame: Baseline and up to 6 years approximately every 3 months ]
  6. HRQoL as assessed by Memorial Anxiety Scale for Prostate Cancer (MAX-PC) [ Time Frame: Baseline and up to 6 years approximately every 3 months ]
  7. HRQoL as assessed by Work Productivity and Activity Questionnaire: Specific Health Problem (WPAI-SHP) [ Time Frame: Baseline and up to 6 years approximately every 3-6 months ]
  8. HRQoL as assessed by Service Satisfaction Scale for Cancer Care (SCA) [ Time Frame: Baseline and up to 6 years approximately every 3-6 months ]

Secondary Outcome Measures :
  1. Number of patients with Physician Factors for Treatment Decisions [ Time Frame: Up to 6 years following enrollment onto the study ]
    Physician-reported primary factor in treatment decision making and identified trigger for change will be categorized as:Progressive disease (by Prostate specific antigen (PSA), radiographic, or other unequivocal clinical progression); Tolerability (Lack of tolerability or intolerable side effects); Availability of investigational product/clinical trial; Specific patient concerns regarding treatment; Insurance coverage/costs; Patient compliance

  2. Number of patients with Clinical outcomes, including PSA values, clinical and/or radiologic evidence of disease progression and overall survival [ Time Frame: Up to 6 years following enrollment onto the study ]
  3. Number of patients with Prognostic factors (e.g., patient and disease characteristics) potentially related to select clinical outcomes and HRQoL [ Time Frame: Up to 6 years following enrollment onto the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult male patients diagnosed with CRPC. Eligible patients will be enrolled by urologists and medical oncologists.

Inclusion Criteria:

Patient Inclusion:

  • Patient may have M0 or M1 disease
  • Confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, as evidenced by a serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) and Clear progressive disease, as evidenced by a minimum of two rising PSA levels measured at least 7 days apart or new clinical or imaging evidence of progressive metastatic disease
  • Initiating the first or second line treatment for CRPC: including anti- androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. Previous first line CRPC treatments are limited to: First generation anti-androgens (bicalutamide, flutamide, or nilutamide) or Sipuleucel-T
  • Patients may be enrolled within 90 days from the time of decision to treat or within 90 days of treatment initiation.
  • Willing and able to complete periodic patient-reported outcome (PRO) questionnaires, with or without assistance
  • Estimated life expectancy of ≥ 6 months

Caregiver Inclusion:

  • Meets the definition of an unpaid relative or friend who helps the patient with his or her activities of daily living
  • Willing and able to complete caregiver-reported outcome questionnaires over the course of the patient's participation in the study

Exclusion Criteria:

Patient Exclusion:

  • Receiving concomitant treatment for other cancer (excluding basal cell carcinoma, squamous cell carcinoma and treatment for hormone sensitive prostate cancer) within 6 months prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02380274

  Hide Study Locations
Layout table for location information
United States, Alabama
Site USSUB1007
Homewood, Alabama, United States, 35209
United States, Alaska
Site USSUB1010
Anchorage, Alaska, United States, 99503
United States, Arizona
Site USSUB1111
Phoenix, Arizona, United States, 85013
Site US1104
Scottsdale, Arizona, United States, 85251
Site US1065
Tucson, Arizona, United States, 85715
Site USSUB1033
Tucson, Arizona, United States, 85741
Site US1121
Yuma, Arizona, United States, 85364
United States, Arkansas
Site US1198
Hot Springs, Arkansas, United States, 71913
United States, California
Site US1229
Fresno, California, United States, 93703
Site US1093
Highland, California, United States, 92346
Site US1085
Laguna Hills, California, United States, 92653
Site US1087
Los Angeles, California, United States, 90048
Site USSUB1038
Marina Del Rey, California, United States, 90292
Site US1167
Sacramento, California, United States, 95608
Site USSUB1026
San Diego, California, United States, 92120
Site US1089
San Diego, California, United States, 92123
Site USSUB1037
San Jose, California, United States, 95124
Site US1148
Santa Monica, California, United States, 90404
Site USSUB1099
Templeton, California, United States, 93465
Site US1055
Torrance, California, United States, 90505
United States, Colorado
Site USSUB1001
Denver, Colorado, United States, 80211
Site US1032
Englewood, Colorado, United States, 80113
Site US1147
Glenwood Springs, Colorado, United States, 81601
United States, Connecticut
Site US1086
Norwich, Connecticut, United States, 06360
Site US1160
Stamford, Connecticut, United States, 06904
United States, Florida
Site US1205
Bay Pines, Florida, United States, 33744
Site USSUB1014
Daytona Beach, Florida, United States, 32114
Site US1129
Fort Lauderdale, Florida, United States, 33308
Site US1101
Fort Myers, Florida, United States, 33908
Site US1073
Hialeah, Florida, United States, 33016
Site US1102
Lakewood Ranch, Florida, United States, 34202
Site US1105
Naples, Florida, United States, 34102
Site US1108
Naples, Florida, United States, 34102
United States, Georgia
Site US1067
Albany, Georgia, United States, 31701
Site USSUB1025
Atlanta, Georgia, United States, 30312
Site US1051
Newnan, Georgia, United States, 30265
Site US1172
Thomasville, Georgia, United States, 31792
United States, Idaho
Site US1066
Boise, Idaho, United States, 83702
Site USSUB1018
Coeur d'Alene, Idaho, United States, 83814
United States, Illinois
Site US1090
Chicago, Illinois, United States, 60612
Site US1184
Crystal Lake, Illinois, United States, 60010
Site US1084
Glenview, Illinois, United States, 60201
Site US1213
Hines, Illinois, United States, 60141
Site US1204
North Chicago, Illinois, United States, 60064
Site US1119
Urbana, Illinois, United States, 61801
United States, Indiana
Site USSUB1035
Greenwood, Indiana, United States, 46143
Site USSUB1009
Jeffersonville, Indiana, United States, 47130
Site US1201
Lafayette, Indiana, United States, 47904
United States, Iowa
Site US1203
Davenport, Iowa, United States, 52807
United States, Kansas
Site USSUB1072
Wichita, Kansas, United States, 67208
Site US1079
Wichita, Kansas, United States, 67226
United States, Kentucky
Site US1139
Ashland, Kentucky, United States, 41101
United States, Louisiana
Site USSUB1049
Baton Rouge, Louisiana, United States, 70809
Site US1181
Covington, Louisiana, United States, 70433
Site US1164
Houma, Louisiana, United States, 70360
Site US1061
New Orleans, Louisiana, United States, 70112
Site US1115
New Orleans, Louisiana, United States, 70121
Site US1004
Shreveport, Louisiana, United States, 71106
United States, Maine
Site US1118
Lewiston, Maine, United States, 04240
United States, Maryland
Site US1052
Bethesda, Maryland, United States, 20889
Site US1133
Greenbelt, Maryland, United States, 20770
Site USSUB1042
Towson, Maryland, United States, 21204
United States, Massachusetts
Site US1077
Worcester, Massachusetts, United States, 01605
Site US1039
Worcester, Massachusetts, United States, 01655
United States, Michigan
Site US1233
Detroit, Michigan, United States, 48201
Site US1187
Lansing, Michigan, United States, 48060
Site US1056
Royal Oak, Michigan, United States, 48073
Site USSUB1143
Troy, Michigan, United States, 48084
United States, Minnesota
Site US1174
Duluth, Minnesota, United States, 55805
Site US1157
Minneapolis, Minnesota, United States, 55455
Site USSUB1063
Saint Cloud, Minnesota, United States, 56303
Site US1151
Saint Louis Park, Minnesota, United States, 55416
Site US1120
Woodbury, Minnesota, United States, 55125
United States, Mississippi
Site US1080
Tupelo, Mississippi, United States, 38801
United States, Missouri
Site US1144
Bolivar, Missouri, United States, 65613
Site US1081
Columbia, Missouri, United States, 65201
Site US1223
Saint Louis, Missouri, United States, 63110
United States, Montana
Site US1123
Billings, Montana, United States, 59101
Site USSUB1062
Billings, Montana, United States, 59101
Site USSUB1048
Missoula, Montana, United States, 59808
United States, Nebraska
Site US1070
Fremont, Nebraska, United States, 68025
Site US1165
Grand Island, Nebraska, United States, 68803
Site US1149
Omaha, Nebraska, United States, 68114
Site USSUB1022
Omaha, Nebraska, United States, 68130
United States, New Jersey
Site US1166
Belleville, New Jersey, United States, 07109
Site US1169
Berkeley Heights, New Jersey, United States, 07922
Site US1059
Edison, New Jersey, United States, 08837
Site USSUB1006
Englewood, New Jersey, United States, 07631
Site US1156
Paramus, New Jersey, United States, 07652
Site USSUB1016
Voorhees, New Jersey, United States, 08043
United States, New Mexico
Site US1053
Albuquerque, New Mexico, United States, 87109
Site US1189
Santa Fe, New Mexico, United States, 87505
United States, New York
Site USSUB1041
Albany, New York, United States, 12208
Site US1068
Bronx, New York, United States, 10461
Site US1226
Buffalo, New York, United States, 14215
Site US1142
Cheektowaga, New York, United States, 14225
Site USSUB1023
East Setauket, New York, United States, 11733
Site US1127
Garden City, New York, United States, 11530
Site US1163
Jamaica, New York, United States, 11432
Site US1071
Manhattan, New York, United States, 10029
Site US1046
Mineola, New York, United States, 11540
Site US1054
North Hills, New York, United States, 11042
Site USSUB1012
Poughkeepsie, New York, United States, 12601
Site USSUB1043
Syracuse, New York, United States, 13210
United States, North Carolina
Site US1044
Asheville, North Carolina, United States, 28801
Site US1064
Concord, North Carolina, United States, 28025
Site US1132
Durham, North Carolina, United States, 27710
Site US1136
Gastonia, North Carolina, United States, 28054
Site USSUB1017
Greenville, North Carolina, United States, 27834
Site USSUB1134
Hendersonville, North Carolina, United States, 28792
Site US1069
High Point, North Carolina, United States, 27262
Site US1030
Pinehurst, North Carolina, United States, 28374
Site USSUB1036
Raleigh, North Carolina, United States, 27612
Site US1078
Washington, North Carolina, United States, 27889
Site US1074
Winston-Salem, North Carolina, United States, 27103
Site US1141
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Site USSUB1011
Cincinnati, Ohio, United States, 45212
Site USSUB1028
Middleburg Heights, Ohio, United States, 44130
United States, Oklahoma
Site USSUB1058
Oklahoma City, Oklahoma, United States, 73104
Site US1137
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Site US1153
Coos Bay, Oregon, United States, 97420
Site US1116
Corvallis, Oregon, United States, 97330
Site US1230
Portland, Oregon, United States, 97239
Site USSUB1020
Springfield, Oregon, United States, 97477
United States, Pennsylvania
Site USSUB1003
Bala-Cynwyd, Pennsylvania, United States, 19004
Site US1100
Lancaster, Pennsylvania, United States, 17604
Site US1218
Pittsburgh, Pennsylvania, United States, 15240
United States, South Carolina
Site US1224
Charleston, South Carolina, United States, 29401
Site USSUB1002
Myrtle Beach, South Carolina, United States, 29572
United States, South Dakota
Site USSUB1095
Watertown, South Dakota, United States, 57201
United States, Tennessee
Site USSUB1031
Chattanooga, Tennessee, United States, 37403
Site US1024
Cookeville, Tennessee, United States, 38501
Site US1128
Nashville, Tennessee, United States, 37208
Site US1131
Nashville, Tennessee, United States, 37209
Site USSUB1088
Nashville, Tennessee, United States, 37232
United States, Texas
Site US1227
Dallas, Texas, United States, 75216
Site US1140
Fort Worth, Texas, United States, 76104
Site US1208
San Antonio, Texas, United States, 78229
Site USSUB1045
Temple, Texas, United States, 76508
United States, Utah
Site US1207
Salt Lake City, Utah, United States, 84148
United States, Virginia
Site US1092
Richmond, Virginia, United States, 23230
Site US1096
Richmond, Virginia, United States, 23235
Site USSUB1005
Virginia Beach, Virginia, United States, 23462
United States, Washington
Site US1083
Bellingham, Washington, United States, 98225
Site US1029
Everett, Washington, United States, 98201
Site US1112
Tacoma, Washington, United States, 98431
United States, Wisconsin
Site US1122
La Crosse, Wisconsin, United States, 54601
Site US1232
Milwaukee, Wisconsin, United States, 53295
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Layout table for investigator information
Study Director: Medical Director APGD, Medical Affairs, Americas

Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc. Identifier: NCT02380274     History of Changes
Other Study ID Numbers: ONC-MA-1004
First Posted: March 5, 2015    Key Record Dates
Last Update Posted: October 21, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
Prostate Cancer
Castration-resistant Prostate Cancer
Metastatic Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases